Tumor Suppressor Gene Allelic Loss Profiles of the Variants of Papillary Thyroid Carcinoma

Diagnostic Molecular Pathology

Volumn 13, Issue 1, 2004, Pages 41-46

  Hunt, Jennifer L ^a,b   Fowler, Melissa ^a   Lomago, Deren ^a   Niehouse, Laura ^a   Sasatomi, Eizaburo ^a   Swalsky, Patricia ^a   Finkelstein, Sydney ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Allelic loss; Loss of heterozygosity; Papillary carcinoma; Thyroid

Indexed keywords

DNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CHROMOSOMAL LOCALIZATION; CHROMOSOME 22Q; CHROMOSOME 9Q; CLINICAL ARTICLE; FEMALE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 1342323560     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200403000-00007     Document Type: Article

References (33)

1. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79:564-573.
2. Filie AC, Chiesa A, Bryant BR, et al. The Tall cell variant of papillary carcinoma of the thyroid: cytologic features and loss of heterozygosity of metastatic and/or recurrent neoplasms and primary neoplasms. Cancer. 1999;87:238-242.
3. Nikiforov YE, Erickson LA, Nikiforova MN, et al. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol. 2001;25: 1478-1484.
4. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342.
5. Rorive S, Eddafali B, Fernandez S, et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol. 2002;15: 1294-1301.
6. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14:55-60.
7. Logani S, Gupta PK, LiVolsi VA, et al. Thyroid nodules with FNA cytology suspicious for follicular variant of papillary thyroid carcinoma: follow-up and management. Diagn Cytopathol. 2000;23:380-385.
8. Hoang-Vu C, Boltze C, Gimm O, et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol. 2002;21:265-272.
9. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTCl-induced thyroid carcinomas. Am J Pathol. 2000;157:671-677.
10. Lo CY, Lam KY, Chan KT, et al. Telomerase activity in thyroid malignancy. Thyroid. 1999;9:1215-1220.
11. Baloch Z, LiVolsi VA, Henricks WH, et al. Encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;118:603-605; discussion 605-606.
12. Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117:143-150.
13. Hunt JL, Dacic S, Barnes EL, et al. Encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;118:602-603;discussion 605-606.
14. Hirokawa M, Carney JA, Goellner JR, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol. 2002;26: 1508-1514.
15. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. 2002;160:2157-2167.
16. Santoro M, Papotti M, Chiappetta G, et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab. 2002;87:370-379.
17. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001;8:345-354.
18. Chiappetta G, Toti P, Cetta F, et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 2002;87:364-369.
19. Sheils OM, O'Leary JJ, Uhlmann V, et al. ret/PTC-1 activation in Hashimoto's thyroiditis. Int J Surg Pathol. 2001;8:185-189.
20. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope. 1997;107:95-100.
21. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174: 462-468.
22. Kitamura Y, Shimizu K, Tanaka S, et al. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer. 2000;27:244-251.
23. Takeuchi Y, Daa T, Kashima K, et al. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid. 1999;9:377-381.
24. Kjellman P, Lagercrantz S, Hoog A, et al. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes. Chromosomes Cancer. 2001;32:43-49.
25. Kjellman P, Learoyd DL, Messina M, et al. Expression of the RET protooncogene in papillary thyroid carcinoma and its correlation with clinical outcome. Br J Surg. 2001;88:557-563.
26. Kroll TG. Molecular rearrangements and morphology in thyroid cancer. Am J Pathol. 2002;160:1941-1944.
27. Asakawa H, Kobayashi T. Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report. Pathology (Phila). 2002;34:94-97.
28. Frisk T, Foukakis T, Dwight T, et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer. 2002;35:74-80.
29. Hunt JL, LiVolsi VA, Baloch ZW, et al. A novel microdissection and genotyping of follicular derived thyoid tumors to predict aggressiveness. Hum Pathol. 2003;34:375-380.
30. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41:236-243.
31. Faggiano A, Talbot M, Baudin E, et al. Differential expression of galectin 3 in solid cell nests and C cells of human thyroid. J Clin Pathol. 2003;56: 142-143.
32. Hunt JL, LiVolsi VA, Baloch ZW, et al. Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. Am J Surg Pathol. 2003;27:159-166.
33. Lin JD, Liou MJ, Chao TC, et al. Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. Endocr Related Cancer. 1999;6:109-115.